变更后营业执照的具体内容如下： 1、公司名称：广生堂中兴（江苏）药业有限公司 2、统一社会信用代码：91321112740660223A 3、住所：镇江市丹徒高新技术产业园冷遹路 86 号 4、企业类型：有限责任公司 5、法定代表人：李援黎 6、注册资本：6428.5714 万元 证券代码：300436 证券简称：广生堂 公告编号：2025045 福建广生堂药业股份有限公司 关于全资子公司变更名称暨完成工商变更登记的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、 完整，没有虚假记载、误导性陈述或重大遗漏。 基于企业经营发展需要，为更好地进行品牌管理和提升品牌影响力，福建广 生堂药业股份有限公司全资子公司江苏中兴药业有限公司更名为"广生堂中兴 （江苏）药业有限公司"，并于近日完成了工商变更登记手续，取得了镇江市丹 徒区政务服务管理办公室换发的营业执照。 1 7、成立日期：2002 年 08 月 03 日 8、经营范围：药品的生产（按《药品生产许可证》所列范围经营）；自营 和代理各类商品及技术的进出口业务（国家限定企业经营或禁止进出口的商品和 技术除外）。（依法须经批准的项目，经相关部门批准后方可开展 ...

Group 1 - Huate Gas plans to reduce its shareholding by up to 2% through block trading from June 9, 2025, to September 8, 2025, totaling no more than 2.4 million shares [1] - Huazhong Co. reported April sales of 208,200 pigs, with a revenue of 375 million yuan, showing a month-on-month decrease of 4.28% [2] - Haizheng Biomaterials intends to reduce its shareholding by up to 1% starting from June 9, 2025, due to funding needs [3] Group 2 - Lisheng Sports plans to repurchase shares worth between 20 million and 40 million yuan for employee stock ownership plans [5] - Hongjing Technology signed a service contract worth 563 million yuan for a smart computing project, lasting five years [6] - Ugreen Technology aims to participate in the pre-restructuring of Zhongzhi Real Estate, targeting 100% equity acquisition [8] Group 3 - Jingquan Hua plans to reduce its shareholding by up to 1.67% starting from June 6, 2025 [9] - New Times plans to reduce its shareholding by up to 0.3% starting from June 6, 2025 [10] - Baofeng Energy intends to repurchase shares worth between 1 billion and 2 billion yuan, with a maximum price of 22.80 yuan per share [10] Group 4 - Yuanli Co. plans to reduce its shareholding by up to 3% starting from June 6, 2025 [14] - Huakai Yibai intends to reduce its shareholding by up to 3% starting from June 6, 2025 [15] - Guangshengtang's innovative hepatitis B drug GST-HG131 has completed Phase II clinical trials, showing significant efficacy [17] Group 5 - Electric Media plans to invest 115 million yuan in a cultural technology venture capital fund, which has a total expected scale of 2 billion yuan [21] - China Merchants Port reported a total of 17.059 million TEUs in April, a year-on-year increase of 6% [23] - Changguang Huaxin plans to reduce its shareholding by up to 2% starting from June 9, 2025 [25] Group 6 - Huace Film plans to reduce its shareholding by up to 1.11% starting from June 6, 2025, to reduce debt [26] - BeiGene's HHLR Fund reduced its shareholding from 6.03% to 4.89% after selling 16 million shares [27] - Heertai plans to reduce its shareholding by up to 2.05% starting from June 6, 2025 [28] Group 7 - Biyin Lefen's director plans to reduce his shareholding by up to 491,300 shares starting from June 6, 2025, due to personal funding needs [29]

证券代码：300436 证券简称：广生堂 公告编号：2025044 福建广生堂药业股份有限公司 关于乙肝治疗创新药 GST-HG131 获得 II 期临床研究总结报告的公告 研究项目：评价 GST-HG131 片在慢性乙型肝炎患者中的安全性、有效性的 随机、双盲、安慰剂对照的 II 期临床研究 临床批件号：CXHL1900412/ CXHL1900413/ CXHL1900414 研究负责单位：中国人民解放军总医院第五医学中心 主要研究者（PI）：王福生院士 主要参与研究者：侯金林教授（南方医科大学南方医院）、黄祖雄教授（福 建医科大学孟超肝胆医院）、蔡大川教授（重庆医科大学附属二医院）等。 本公司及董事会全体成员保证信息披露的内容真实、准确、 完整，没有虚假记载、误导性陈述或重大遗漏。 福建广生堂药业股份有限公司（简称"公司"）乙肝治疗创新药 GST-HG131 已完成慢性乙型肝炎 II 期临床试验，并于近日获得 II 期临床试验的研究总结报 告。研究结果显示，GST-HG131 片对慢性乙型肝炎患者的乙肝表面抗原 HBsAg 有明显抑制效果，且安全性良好。现将有关内容公告如下： 一、基本情况 研究药物：G ...

Group 1: Clinical Trial Progress - The clinical trial for GST-HG131 has completed its IIa phase, with patient enrollment finished in January 2025 [1] - GST-HG141 has completed its II phase and is currently preparing for the III phase trial [2][4] - Both GST-HG131 and GST-HG141 are included in the breakthrough therapy designation, with ongoing preparations for their respective clinical trials [3][4] Group 2: Funding and Financial Strategy - The company is seeking to expand its funding sources through a significant capital increase to support clinical trials [2] - The long development cycle of innovative drugs necessitates a robust financial strategy to ensure funding for clinical projects [2] - The company emphasizes cost reduction and revenue enhancement to meet clinical project funding needs [2] Group 3: Innovation and Product Pipeline - Since its listing in 2015, the company has transitioned to an innovative drug enterprise, developing multiple drugs in various therapeutic areas [2] - The company has established a pipeline of innovative drugs, including treatments for COVID-19 and hepatitis B [2] - The company plans to continue expanding its innovative drug pipeline and strengthen its R&D team [4][5] Group 4: Brand Development in Traditional Chinese Medicine - The company is collaborating with health industry partners to enhance its brand in the traditional Chinese medicine sector [5] - A new partnership aims to introduce and industrialize traditional Chinese medicine formulas, focusing on high-quality products [5]

证券代码：300436 证券简称：广生堂 公告编号：2025043 福建广生堂药业股份有限公司 本公司及董事会全体成员保证信息披露的内容真实、准确、 完整，没有虚假记载、误导性陈述或重大遗漏。 关于参加 2025 年福建辖区上市公司投资者网上集体接待日 活动的公告 福建广生堂药业股份有限公司董事会 2025 年 5 月 9 日 为进一步加强与投资者的互动交流，福建广生堂药业股份有限公司（以下简 称"公司"）将参加由福建证监局指导，福建省上市公司协会主办与深圳市全景 网络有限公司联合举办的"2025 年福建辖区上市公司投资者网上集体接待日活 动"，现将相关事项公告如下： 1 本次活动将采用网络远程的方式举行，投资者可登录"全景路演"网站 (http://rs.p5w.net)，或关注微信公众号：全景财经，或下载全景路演 APP， 参与本次互动交流，活动时间为 2025 年 5 月 14 日（周三）15:30-17:00。届时 公司高管将在线就公司 2024 年度业绩、公司治理、发展战略、经营状况、融资 计划、股权激励和可持续发展等投资者关心的问题，与投资者进行沟通与交流， 欢迎广大投资者踊跃参与! 特此公告。 ...

证券代码：300436 证券简称：广生堂 公告编号：2025042 福建广生堂药业股份有限公司 关于 2024 年年度股东大会决议的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 特别提示： 1、本次股东大会未出现否决议案的情形； 2、本次股东大会未涉及变更以往股东大会已通过的决议。 一、会议召开和出席情况 （一）会议召开时间： 1、现场会议召开时间：2025 年 5 月 9 日（星期五）14:00 2、网络投票时间： （1）通过深圳证券交易所交易系统进行网络投票的具体时间为：2025 年 5 月 9 日 9:15—9:25，9:30—11:30 和 13:00—15:00。 （2）通过深圳证券交易所互联网投票系统投票的具体时间为：2025 年 5 月 9 日 9:15—15:00。 （二）现场会议召开地点：福建省福州市闽侯县福州高新区乌龙江中大道 7 号海西高新技术产业园创新园二期 16 号楼 13F 会议室 （三）会议召集人：公司董事会 （四）会议主持人：董事长李国平先生 （五）会议召开方式：现场表决与网络投票相结合的方式 （六）会议召开的合法、合规 ...

国浩律师（上海）事务所 关 于 关于福建广生堂药业股份有限公司 2024 年年度股东大会之法律意见书 致：福建广生堂药业股份有限公司 福建广生堂药业股份有限公司 2024 年年度股东大会 之 法律意见书 上海市静安区山西北路 99 号苏河湾中心 MT25-28 楼 邮编：200085 25-28/F, Suhe Centre, 99 North Shanxi Road, Jing'an District, Shanghai 200085, China 电话/Tel: +86 21 5234 1668 传真/Fax: +86 21 5234 1670 网址/Website: http://www.grandall.com.cn 二零二五年五月 国浩律师（上海）事务所 福建广生堂药业股份有限公司（以下简称"公司"）2024 年年度股东大会于 2025 年 5 月 9 日召开。国浩律师（上海）事务所（以下简称"本所"）经公司聘 请，委派律师出席现场会议，并根据《中华人民共和国公司法》（以下简称"《公 司法》"）、《中华人民共和国证券法》（以下简称"《证券法》"）等法律、 法规及中国证券监督管理委员会（以下简称"中国 ...

本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 证券代码：300436 证券简称：广生堂 公告编号：2025041 福建广生堂药业股份有限公司 关于实际控制人部分股份解除质押及质押的公告 福建广生堂药业股份有限公司（以下简称"公司"）近日收到实际控制人李 国平先生的通知，获悉其所持有公司部分股份办理了解除质押及质押手续，最终 质押股数未发生变化。具体情况如下： 一、股东股份解除质押及质押的基本情况 | 股东 | 是否为控股 股东或第一 | 本次解除质 | 占其所 持股份 | 占公司 总股本 | 起始时间 | 解除时间 | 质权人 | | --- | --- | --- | --- | --- | --- | --- | --- | | 名称 | 大股东及其 | 押数量（股） | | | | | | | | | | 比例 | 比例 | | | | | | 一致行动人 | | | | | | | | 李国平 | 是 | 5,180,000 | 57.55% | 3.25% | 2022.4.29 | 2025.4.28 | 华西证券股 | | 李国平 | 是 | ...

Group 1: Innovation and R&D Progress - The company has initiated multiple innovative drug projects, with GST-HG141 completing Phase II clinical trials and preparing for Phase III trials [1] - The R&D investment for 2024 is 44.8861 million yuan, accounting for 10.17% of operating revenue, while the cumulative R&D investment from 2022 to 2024 is approximately 546 million yuan, representing 43.69% of cumulative operating revenue [1] Group 2: Financial Performance and Challenges - In 2024, the company reported a net loss of 172 million yuan, with a net profit attributable to shareholders of 156 million yuan, indicating ongoing financial challenges despite improved operational quality [4] - The gross margin for hepatitis products has been under pressure due to ongoing centralized procurement policies, leading to increased depreciation and amortization costs [4] - The company's revenue continued to grow, with a year-on-year increase of approximately 19.87% in core liver disease medications, excluding the impact of the COVID-19 drug [4] Group 3: Future Strategies and Market Outlook - The company aims to focus on breakthrough advancements in its core hepatitis drug pipeline and enhance capital operations to support clinical research funding [2] - The overall pharmaceutical market is expected to grow due to factors such as population aging, increased chronic disease prevalence, and supportive government policies for innovative drug development [3] - The company plans to combine generic and innovative drug strategies while emphasizing cost control and efficiency improvements to achieve profitability [2]

智通财经4月24日讯（记者 王俊仙 何凡）乙肝临床治愈新药的临床研发取得实质性进展，令广生堂 (300436.SZ)的市场关注度持续升温。今日晚间，广生堂披露全球首个三联全口服治疗方案获批开展II期 临床，而由于该II期临床试验被纳入优化创新药临床试验审评审批试点项目，业内预计项目后续临床进 度有望加速。 "能被纳入试点的项目在创新药、临床数据和药物作用机制等方面的要求较高，一旦被纳入将提升审评 审批效率，缩短审评周期，有助于助推联合方案尽早上市。"资深医药行业专家郭新峰告诉智通财经记 者，GST-HG131和GST-HG141两者分别针对抗乙肝病毒不同新靶点，在作用机制上预计存在协同互 补，而且该三联方案是全口服，有助于提升患者依从性，若最终能成功上市有望填补抗乙肝病毒类临床 治愈创新药的空白。 据智通财经记者了解，这是全球首个由两个完成II期临床入组的潜在First-in-class创新药组成的全口服方 案。 此前，广生堂曾因乙肝单药的临床数据而连续大涨，市场亦期待广生堂这家老牌乙肝治疗企业能依靠这 些创新疗法"焕发第二春"，实现从传统药企向乙肝创新领域的"关键一跃"。 三联方案临床验证有望加速推进 今年 ...